image credit- shutterstock
Siemens Healthineers and Apollo Hospitals have announced a research collaboration founded on a shared ambition to advance innovations in artificial intelligence (AI) and imaging technologies, with the goal of improving lives.
The research, spanning quantitative ultrasound imaging to AI-driven clinical solutions, aims to enhance liver disease management by improving patient care pathways and outcomes, from early detection and risk stratification to monitoring intervention and therapy response.
The partnership combines technical and clinical expertise to develop innovative healthcare solutions for the growing burden of liver diseases in India, focusing on early diagnosis, accurate detection, and precise monitoring to improve patient outcomes.
As per Government of India guidelines, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), referred to as NAFLD in the report, is a growing cause of liver disease in India. Prevalence ranges from 9% to 32%, higher among those who are overweight, obese, or have diabetes. NFHS-4 (2015-2016) reports 18-20% of adults are overweight/obese and 3-8% have abnormal blood sugar. MASLD significantly increases cardiovascular risk, with heart disease being the leading cause of death.
Following the 2024 Memorandum of Understanding, the Master Research Agreement (MRA) was formalised in March 2025, establishing a foundation for collaborative research in diagnostic and interventional ultrasound imaging. The signing ceremony for the MRA Addendum was held on July 23, 2025, in Hyderabad, marking a significant milestone in this partnership.
